Cargando…

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer

In the phase III EMERALD trial, treatment with elacestrant significantly improved progression-free survival compared with investigator’s choice in patients with estrogen receptor-positive metastatic breast cancer that progressed on prior endocrine therapies.

Detalles Bibliográficos
Autor principal:	Jacobson, Anne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Conference Perspectives: Highlights from SABCS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963147/ https://www.ncbi.nlm.nih.gov/pubmed/35348779 http://dx.doi.org/10.1093/oncolo/oyac015

Ejemplares similares

Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
por: Jacobson, Anne
Publicado: (2022)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Ribociclib Improves Overall Survival in HR+/HER2– Metastatic Breast Cancer Across Common Genomic and Clinical Subtypes
por: Jacobson, Anne
Publicado: (2022)

Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score
por: Jacobson, Anne
Publicado: (2022)

SABCS 2021 Insights on Breast Cancer Research: An Interview with Dr. Laura Spring
por: Jacobson, Anne
Publicado: (2022)

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Elacestrant: First Approval
por: Hoy, Sheridan M.
Publicado: (2023)

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
por: Bidard, Francois-Clement, et al.
Publicado: (2022)

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
por: Olivier, Timothée, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
por: Conlan, Maureen G., et al.
Publicado: (2020)

Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women
por: Conlan, Maureen G., et al.
Publicado: (2020)

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
por: Bardia, Aditya, et al.
Publicado: (2021)

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using (18)F-FES PET/CT imaging
por: Jager, Agnes, et al.
Publicado: (2020)

Peering into the Brain’s Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders
por: Arjmand, Shokouh, et al.
Publicado: (2023)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
por: Varella, Leticia, et al.
Publicado: (2023)

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Hong, Shaodong, et al.
Publicado: (2016)

Estrogen receptor and aryl hydrocarbon receptor signaling pathways
por: Matthews, Jason, et al.
Publicado: (2006)

Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
por: Pathan, Faruque, et al.
Publicado: (2021)

Degree of Early Estrogen Response Predict Survival after Endocrine Therapy in Primary and Metastatic ER-Positive Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

JUPITER‐02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps
por: Tan, Laura Ling Ying, et al.
Publicado: (2021)

Molecular Mechanisms of Endocrine Resistance in Estrogen-Receptor-Positive Breast Cancer
por: Belachew, Esmael Besufikad, et al.
Publicado: (2021)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Extracellular vesicle production in Gram‐positive bacteria
por: Dean, Scott N., et al.
Publicado: (2021)

Immune receptor mimicking hormone receptors: a new guarding strategy
por: Liu, Xueru, et al.
Publicado: (2023)

Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer
por: Hagio, Kanako, et al.
Publicado: (2021)

Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
por: Reinert, Tomás, et al.
Publicado: (2017)

A glimpse of endocrine pancreas development from single-cell analyses
por: Gao, Ce, et al.
Publicado: (2018)

Serial progression of cortical and medullary thymic epithelial microenvironments
por: Alves, Nuno L, et al.
Publicado: (2014)

Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives
por: Ditonno, Ilaria, et al.
Publicado: (2021)

Editorial: Estrogen receptors in endocrine disorders
por: Filardi, Tiziana, et al.
Publicado: (2023)

Innate lymphoid cells and cancer: Role in tumor progression and inhibition
por: Yuan, Xiaodong, et al.
Publicado: (2021)

Multi‐host lifestyle in plant‐beneficial bacteria: an evolutionary advantage for survival and dispersal?
por: Matilla, Miguel A., et al.
Publicado: (2022)

Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer
por: Shen, Lin
Publicado: (2018)

Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
por: Kelly, Patrick, et al.
Publicado: (2017)

Regulatory function of the P295-T311 motif of the estrogen receptor α - does proteasomal degradation of the receptor induce emergence of peptides implicated in estrogenic responses?
por: Gallo, Dominique, et al.
Publicado: (2008)

Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer
por: Yamashita, Hiroko, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_97tc8g066h4oqrakduiije65uh